UROTHELIAL CANCER

This study tests a drug called erdafitinib against standard treatments (chemotherapy or pembrolizumab) in people with advanced bladder cancer that has specific FGFR gene changes. The goal is to see if erdafitinib helps people live longer. About 629 adults whose cancer worsened af…

This study tests two different doses of an experimental drug called erdafitinib in people with advanced bladder cancer that has spread or cannot be removed by surgery and has certain FGFR gene changes. The main goal is to see how well the drug shrinks tumors. About 239 participan…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding immunotherapy to standard chemotherapy helps people with advanced bladder cancer live longer. About 1,300 participants who have not had prior treatment for inoperable or metastatic uro…

This study tests two new drug combinations (tobemstomig alone or with tiragolumab) against a standard drug (atezolizumab) in people with advanced bladder cancer who cannot receive platinum chemotherapy. The goal is to see if these combinations are safer and work better. About 204…

This study tests a new drug, BT5528, given alone or with another drug (nivolumab) in people with advanced solid tumors that have high levels of a protein called EphA2. The main goals are to find safe doses and learn about side effects. The study also checks if the drug can shrink…

This study was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer who had not received prior treatment. The goal was to see if the combination was safe and helped control the cancer. However, the tri…

This study offers continued treatment with avelumab to cancer patients who are already benefiting from it in earlier Pfizer studies. It includes safety monitoring and survival follow-up for people with advanced cancers like lung, ovarian, and bladder cancer. The goal is to keep p…

This study tested two immunotherapy drugs (durvalumab alone or combined with tremelimumab) against standard chemotherapy in over 1,100 people with stage IV bladder cancer that could not be removed by surgery. The goal was to see if these treatments helped people live longer. The …

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study creates a large registry of over 3,500 people, including those with and without urothelial cancer (bladder, ureter, or kidney pelvis cancer). Researchers collect saliva samples and health information to find genetic markers and risk factors linked to the disease. The g…